Marketable Securities

3 Months Ended

Mar. 31, 2020

Note 2. Marketable Securities

MEDITECH follows the provisions of ASC 321, Investments - Equity Securities, which requires marketable securities recorded at fair value and the unrealized change in marketable securities recorded within the income statement.

MEDITECH follows the provisions of ASC 820-10, Fair Value Measurements and Disclosures, which provides for expanded disclosure and guidelines to determine fair value of assets and liabilities. ASC 820-10 applies whenever other standards require or permit assets and liabilities to be measured at fair value, but does not expand the use of fair value in any new circumstances. MEDITECH's marketable securities represent assets measured at fair value on a recurring basis, and are considered Level 1 assets as defined by ASC 820-10.

The following table indicates the original cost, unrealized pretax gains and losses, and fair market value of MEDITECH's securities.

	Dec 31, 2019	Mar 31, 2020

Original cost	$309,435,273	$299,435,273
Unrealized pretax gains	113,038,406	61,328,045
Unrealized pretax losses	(919,180)	(24,406,463)

Fair market value	$421,554,499	$336,356,855

During the first quarter of 2020, the fair value of the Company's investment portfolio decreased as a result of significant declines felt throughout the US stock market with the outbreak of the COVID-19 pandemic. The impact of continued volatility is uncertain.